Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

Our client was looking to identify the price point that would maximise revenue from their new vaccine across 8 emerging markets in Latin America and Asia Pacific, as well as establish long-term projections for their forecasting model. In parallel, they needed to ensure widespread and rapid market penetration of the vaccine, taking into account factors such as consumer socio-economic group, age and household composition.
 

read more »

  • Posted by Brett Gardiner, Rachel Howard & Suzan Serip
  • June 12, 2020
  • Articles

The unprecedented challenge of pricing a coronavirus vaccine

The unprecedented challenge of pricing a coronavirus vaccine

Using findings from our recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read our latest article for pharmaphorum.

The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewarding innovation and supporting further research and development. The need for a SARS-CoV-2 vaccine is arguably more urgent, and more global, than ever before for a vaccine. As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to what a responsible pricing strategy might look like. At the same time, payers are also faced with needing to prepare and plan for how to react and manage this situation.

read more »

Catching up with Coronavirus: The race to contain the outbreak is on

Catching up with Coronavirus: The race to contain the outbreak is on

As Coronavirus continues to spread across the globe, Rachel Howard explores what pharma is doing to advance research into the virus, considering lessons learned from previous public health emergencies of international concern.

Over the last month, our newsfeeds have increasingly been dominated by updates on the novel coronavirus (COVID-19) outbreak. Believed to have originated in a live animal market in the Chinese city of Wuhan, at the time of publishing COVID-19 has registered over 75,000 confirmed cases and 2000 deaths, with 29 countries and territories affected. nCoV is in the same family as SARS (Severe Acute Respiratory Syndrome), another strain of coronavirus identified in 2003. While nCoV looks likely to have a lower fatality rate, it has spread much more quickly, with the number of reported cases already having rapidly overtaken SARS and continuing to grow by the day. All indications suggest the virus is highly contagious – including, critically, at the stage before an individual displays any symptoms of infection. This outbreak was declared as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) on 30th January 2020, making it the sixth such emergency since the International Health Regulations came into force in 2005: H1N1 influenza virus (swine flu) in 2009 Wild poliovirus resurgence in 2014 West Africa Ebola virus 2014 Zika virus in 2016 Kivu Ebola virus in 2019 Declaring an outbreak as a PHEIC, in…

read more »

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

Our client’s vaccine to protect against a condition prevalent in older adults had recently launched and secondary research was required to enable them to understand more about their target healthcare consumer and attitudes to health, well-being and vaccination. They needed to build a complete picture of how consumers are influenced, such as whether they are more influenced by HCP advice or online forums and social media. Furthermore they needed to develop an understanding for other out-of-pocket (OOP) competitor vaccines and what the future healthcare initiatives mean for vaccination in general.
 

read more »

The vaccine opportunity in Asia infographic

The vaccine opportunity in Asia infographic

Asia is the home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high awareness levels of the benefits of immunisation are the major factors boosting the vaccine market growth. In our latest infographic we explore the vaccine opportunity in Asia, packed full with all of the latest facts and figures from the region.

read more »